Biren Amin analyst PIPER SANDLER

Currently out of the existing stock ratings of Biren Amin, 41 are a HOLD (20.2%), 161 are a BUY (79.31%), 1 are a SELL (0.49%).

Biren Amin

Work Performance Price Targets & Ratings Chart

Analyst Biren Amin, currently employed at PIPER SANDLER, carries an average stock price target met ratio of 58.38% that have a potential upside of 35.39% achieved within 289 days. Previously, Biren Amin worked at JEFFERIES.

Biren Amin’s has documented 397 price targets and ratings displayed on 52 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ARDX, Ardelyx at 09-Jan-2026.

Wall Street Analyst Biren Amin

Analyst best performing recommendations are on ZNTL (ZENTALIS PHARMACEUTICALS LLC).
The best stock recommendation documented was for ZNTL (ZENTALIS PHARMACEUTICALS LLC) at 5/18/2020. The price target of $44 was fulfilled within 1 day with a profit of $4.35 (10.97%) receiving and performance score of 109.71.

Average potential price target upside

AGEN Agenus ALKS Alkermes Plc ALLO Allogene Therapeutics BLCM Bellicum Pharmaceuticals BLUE Bluebird bio CCCC C4 Therapeutics  CRTX Cortexyme FATE Fate Therapeutics HRTX Heron Therapeuti IMGN ImmunoGen MDCO The Medicines Company NBIX Neurocrine Biosciences NLNK NewLink Genetics REGN Regeneron Pharmaceuticals TRVN Trevena CLDX Celldex Therapeutics ACRX AcelRx Pharmaceuticals ANAB AnaptysBio CTMX CytomX Therapeutics IOVA Iovance Biotherapeutics LUMO Lumos Pharma KDMN Kadmon Holdings ZYNE Zynerba Pharmaceuticals STML Stemline Therapeutics XENE Xenon Pharmaceuticals ARDX Ardelyx GLYC GlycoMimetics KALA Kala Pharmaceuticals NK NantKwest OBSV ObsEva SA VSTM Verastem NERV Minerva Neurosciences ZNTL Zentalis Pharmaceuticals Llc ADVM Adverum Biotechnologies ACLX Arcellx APLS Apellis Pharmaceuticals IMNM Immunome  SRPT Sarepta Therapeutics VKTX Viking Therapeutics CRGX CARGO Therapeutics, Common Stock ARCT Arcturus Therapeutics Holdings BBIO BridgeBio Pharma BCYC Bicycle Therapeutics Ltd CLLS Cellectis SA EQ Equillium IBRX Immunitybio IMTX Immatics NV LEGN Legend Biotech Corp NLTX Neoleukin Therapeutics MNPR Monopar Therapeutics OCUL Ocular Therapeutix SLDB Solid Biosciences LLC

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 04-Jun-2025

$23

$19.76 (609.88%)

$25

4 months 20 days ago
(10-Sep-2025)

5/11 (45.45%)

$18.17 (376.19%)

264

Buy Since 08-Nov-2023

$11

$7.76 (239.51%)

$18

1 years 2 months 12 days ago
(18-Nov-2024)

2/4 (50%)

$8.37 (318.25%)

96

Buy Since 29-Mar-2023

$5

$1.76 (54.32%)

$7.85

1 years 10 months 12 days ago
(18-Mar-2024)

2/2 (100%)

$-5.59 (-52.79%)

207

Buy Since 02-Mar-2022

$8.15

$4.91 (151.54%)

$8.15

2 years 10 months 2 days ago
(28-Mar-2023)

3/3 (100%)

$-20.9 (-71.94%)

465

Buy

$6.87

$5.74 (507.96%)

4 years 10 months 14 days ago
(16-Mar-2021)

0/1 (0%)

$3.72 (118.10%)

Show more analysts

Please expand the browser size to see the chart

Which stock is Biren Amin is most bullish on?

Potential upside of $20.73 has been obtained for OCUL (OCULAR THERAPEUTIX)

Which stock is Biren Amin is most reserved on?

Potential downside of -$5.13 has been obtained for SRPT (SAREPTA THERAPEUTICS)

What Year was the first public recommendation made by Biren Amin?

On 2012

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?